Tetrapyrroles and derivatives
FRONTIER SPECIALTY CHEMICALS INC PROTOPORPHYRIN IX 8-13-B 100MG
NC2876533 PROTOPORPHYRIN IX 8-13-B 100MG
Abcam SB 203580, p38 MAPK inhibitor, 500UG
MW 377.4 Da, Purity >99%. SB 203580, p38 MAPK inhibitor. Achieve your results faster with highly validated, pure and trusted compounds.
The product is subject to the following: Abcam Restricted Use Statement
Abcam UDP-glucose, Highly P2Y14 agonist, 100MG
MW 610.27 Da. Highly potent, endogenous P2Y14 agonist (EC50 = 82 nM). Involved in modulation of gastric function. UDP also available (ab120383).
The product is subject to the following: Abcam Restricted Use Statement
Abcam x estospongin C, IP3 receptor antagonist, 10UG
MW 446.72 g/mol, Purity >90%. Potent, selective, reversible IP₃ receptor antagonist (IC₅₀ = 350 nM). Inhibits IP₃-mediated Ca²+ release from ER and SR. 30-Fold selectivity over ryanodine receptor. Inhibits voltage-dependent Ca²+ and K+ channels at higher concentrations. Cell-permeable.
The product is subject to the following: Abcam Restricted Use Statement
Abcam CL-316243 disodium salt, adrenergic-beta3 receptor agonist, 5MG
MW 465.8 Da, Purity >99%. Selective adrenergic-β3 receptor agonist. Induces adipose tissue remodelling in rat. Hypoglycemic agent. Active *in vivo* and *in vitro*.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Cytochalasin D, actin polymerization inhibitor, 1MG
MW 507.6 Da, Purity >98%. Cytochalasin D, actin polymerization inhibitor. Achieve your results faster with highly validated, pure and trusted compounds.
The product is subject to the following: Abcam Restricted Use Statement
Abcam (R)-CPP, NMDA antagonist, 50MG
MW 252.2 Da. Highly potent, competitive NMDA antagonist; more active enantiomer of (RS)-CPP (ab120160). (Ki values are 0.04, 0.3, 0.6 and 2.0 μM at NR1/NR2A, NR1/NR2B, NR1/NR2C and NR1/NR2D, respectively).
The product is subject to the following: Abcam Restricted Use Statement
Abcam CK 666, Actin polymerization inhibitor, 50MG
MW 296.3 Da, Purity >99%. Potent inhibitor of actin polymerization. Inhibits the Arp2/3 (IC₅₀ = 17 μM), SpArp2/3 (IC₅₀ = 5 μM) and HsArp2/3 complexes (IC₅₀= 4 μM) by preventing a shift into an active conformation.
The product is subject to the following: Abcam Restricted Use Statement
Abcam U-69593, kappa1-opioid receptor agonist, 5MG
MW 356.5 Da, Purity >99%. Potent, selective κ1-opioid receptor agonist (EC50 = 80-109 nM). Active *in vivo*. Antinociceptive.
The product is subject to the following: Abcam Restricted Use Statement
Abcam 3-Morpholinosydnonimine hydrochloride (SIN-1 hydrochloride), Vasodilator, 20MG
MW 206.63 Da, Purity >99%. Releases NO, superoxide and peroxynitrite under physiological conditions. Potent vasodilator and inhibitor of platelet aggregation. Active metabolite of molsidomine (ab142914). Protective in myocardial ischemia-reperfusion. Orally active.
The product is subject to the following: Abcam Restricted Use Statement
Abcam 4-Thiouridine, RNA synthesis inhibitor, 100MG
MW 260.27 Da, Purity >99%. Ribonucleoside (Uridine ab143255) analog. Antisense agent. RNA synthesis inhibitor. Modifies oligos slated for RNA. Induces p53 and inhibits proliferation. Metabolically labels RNA for stability studies.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Necrostatin-1, necroptosis inhibitor, 10MG
MW 259.33 Da, Purity >99%. Potent, specific necroptosis inhibitor (EC₅₀ = 490 nM). Selective allosteric inhibitor of death domain receptor-associated adaptor kinase RIP1 in vitro (EC₅₀ = 182 nM). Caspase independent, programmed necrosis pathway.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Clozapine N-o x ide, Metabolite of Clozapine, 100MG
MW 342.8 Da, Purity >99%. Metabolite of atypical antipsychotic Clozapine (ab120019). Active in vitro and in vivo.
The product is subject to the following: Abcam Restricted Use Statement
Abcam JC-1, Mitochondrial membrane potential dye, 5MG
MW 652.2 Da, Purity >95%. Mitochondrial membrane-potential dye. Exhibits potential-dependent accumulation in mitochondria. Fluorescence emission shift from green (~529 nm) to red (~590 nm). Depolarization is indicated by a decrease in the red/green fluorescence intensity ratio.
The product is subject to the following: Abcam Restricted Use Statement
Abcam x estospongin C, IP3 receptor antagonist, 50UG
MW 446.72 g/mol, Purity >90%. Potent, selective, reversible IP₃ receptor antagonist (IC₅₀ = 350 nM). Inhibits IP₃-mediated Ca²+ release from ER and SR. 30-Fold selectivity over ryanodine receptor. Inhibits voltage-dependent Ca²+ and K+ channels at higher concentrations. Cell-permeable.
The product is subject to the following: Abcam Restricted Use Statement